The Longevity Science Foundation has extended its Invested in Her campaign deadline to October 1, 2026, targeting $250,000 to fund early-stage research into ovarian aging and menopause—a critical gap in women's health science that receives less than 1% of NIH funding despite its systemic impact on cardiometabolic, neurological, and skeletal health across the lifespan.
Key Points
- Women live longer than men but spend more years in poor health due to underfunded reproductive aging
- Ovarian decline cascades across cardiometabolic, brain, and skeletal systems throughout aging
- LSF funds measurement, biological understanding, and early-stage interventions as coordinated pillar
Longevity Analysis
Reproductive aging in women represents a modifiable biological transition with downstream consequences across multiple physiological systems—from metabolic regulation and cardiovascular function to cognitive resilience and bone remodeling. The current research gap means these cascading changes go largely unmeasured and unaddressed until disease symptoms appear. Closing this funding gap directly enables earlier signal detection, mechanistic understanding of how reproductive hormonal shifts propagate systemic decline, and the development of preventive interventions before poor health outcomes crystallize. This positions reproductive aging research not as isolated women's health, but as foundational to understanding and modifying the entire arc of human aging.
Original published by LifeSpan.io, by Press release.